摘要
目的讨论思考比索洛尔分别联合缬沙坦、贝那普利治疗慢性心衰患者的临床效果差异性。方法抽选于2017年6月—2019年12月期间漯河市第三人民医院共收治的慢性心衰患者80例入组,根据计算机随机均分为两组。甲组(n=40)应用比索洛尔联合缬沙坦治疗,乙组(n=40)应用比索洛尔联合贝那普利治疗。评价及对比两组的疗效、心脏指标、血压、心率、不良反应。结果甲组的总有效率为92.5%,乙组的总有效率为82.5%,甲组总有效率高于乙组(P<0.05);甲组的LVESD指标(46.69±1.82)mm、LVEDD指标(51.10±1.39)mm均低于乙组LVESD指标(52.53±2.07)mm、LVEDD指标(57.22±1.55)mm(P<0.05);甲组的LVEF指标(51.26±9.48)%、SV指标(85.35±6.01)mL均高于乙组(P<0.05)LVEF指标(46.90±8.14)%、SV指标(78.41±6.20)mL;甲组的收缩压(107.22±11.57)mm Hg、舒张压(75.16±9.25)mm Hg、心率(81.07±8.77)次/min均低于乙组收缩压(113.29±12.04)mm Hg、舒张压(83.48±10.03)mm Hg、心率(86.40±8.95)次/min(P<0.05);甲组的不良反应率(10%)低于对照组(22.5%)(P<0.05)。结论比索洛尔分别联合缬沙坦、贝那普利治疗慢性心衰患者均可取得一定疗效,其中比索洛尔联合缬沙坦的治疗优势更大,可有效改善心功能,降压、减缓心率效果明显,且不良反应少,具有较高用药安全性,值得临床借鉴应用。
Objective To discuss the difference of clinical effect of bisoprolol combined with valsartan and benazepril in the treatment of chronic heart failure.Methods Totally 80 patients with chronic heart failure admitted to our hospital from June 2017 to December 2019 were randomly divided into two groups according to the computer.Group A(n=40)was treated with bisoprolol and valsartan,group B(n=40)with bisoprolol and benazepril.To evaluate and compare the curative effect,heart index,blood pressure,heart rate and adverse reactions of the two groups.Results The total effective rate of group A was 92.5%,that of group B was 82.5%,and that of group A was higher than that of group B(P<0.05)Compared with group B(P<0.05),LVEF(46.90±8.14)%,SV(78.41±6.20)mL,systolic blood pressure(107.22±11.57)mm Hg,diastolic blood pressure(75.16±9.25)mm Hg,heart rate(81.07±8.77)times/min in group A were lower than those in group B(113.29±12.04)mm Hg,diastolic blood pressure(83.48±10.03)mm Hg,heart rate(86.40±8.95)times/min(P<0.05),and adverse reaction rate in group A was lower(10%)was lower than that of the control group(22.5%)(P<0.05).Conclusion Bisoprolol combined with valsartan and benazepril respectively can achieve certain curative effect in the treatment of chronic heart failure,among which bisoprolol combined with valsartan has greater therapeutic advantage,can effectively improve heart function,reduce blood pressure,slow down heart rate,and has less adverse reactions,and has higher drug safety,which is worthy of clinical reference.
作者
罗书发
LUO Shu-fa(The Third People’s Hospital of Luohe City,Luohe,Henan 462000,China)
出处
《医药论坛杂志》
2020年第7期76-78,84,共4页
Journal of Medical Forum
关键词
比索洛尔
缬沙坦
贝那普利
慢性心衰
Bisoprolol
Valsartan
Benazepril
Chronic heart failure
